MedTrace Logo

Aflibercept in Polypoidal Choroidal Vasculopathy

NCT02120950 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 333

Last updated 2020-12-02

Study results available
· View outcomes & findings →

Summary

To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration

Conditions

  • Neovascular Macular Degeneration

Interventions

DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Eylea is administered as an intravitreal injection

OTHER

Visudyne

Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-29
Primary Completion
2016-08-12
Completion
2017-07-07

Countries

  • Australia
  • Germany
  • Hong Kong
  • Hungary
  • Japan
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02120950 on ClinicalTrials.gov